The GH/IGF-1 axis in chronic heart failure

Area of Science:

• Endocrinology
• Cardiology
• Metabolic Research

Background:

• Chronic Heart Failure (CHF) is traditionally linked to neurohormonal overactivity.
• Emerging evidence suggests hormone down-regulation, including the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF-1) axis, in CHF patients.
• The GH/IGF-1 axis is crucial for cardiac growth, contractility, and vascular function.

Purpose of the Study:

• To discuss the biological actions of GH and IGF-1.
• To explore the cardiovascular implications of GH deficiency and excess.
• To examine the relationship between the somatotrophic axis and CHF, including therapeutic strategies and evidence gaps.

Main Methods:

• Review of existing literature on the GH/IGF-1 axis in cardiovascular health and CHF.
• Analysis of findings from placebo-controlled trials investigating GH therapy in CHF patients.
• Discussion of factors influencing individual responsiveness to GH therapy.

Main Results:

• Impaired GH/IGF-1 axis activity, characterized by low IGF-1, GH deficiency (GHD), and GH resistance, is frequently observed in CHF.
• These abnormalities correlate with disease severity, poor clinical status, and adverse outcomes.
• Clinical trials of GH therapy in CHF have yielded conflicting results, suggesting that the degree of GH/IGF-1 impairment influences treatment efficacy.

Conclusions:

• The GH/IGF-1 axis plays a significant role in cardiovascular regulation and is dysregulated in CHF.
• GH therapy's effectiveness in CHF is variable and may depend on the specific profile of GH/IGF-1 axis impairment.
• Further research is needed to clarify therapeutic strategies, safety, and optimal patient selection for GH-based interventions in CHF.